Skip to main content
SpringerLink
Log in

Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment

  • Published:
Biotechnology and Bioprocess Engineering Aims and scope Submit manuscript

Abstract

With particular regards to the hepatitis A virus (HAV), a terminal dry-heat treatment (100°C for 30 min) process, following lyophilization, was developed to improve the virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate. The loss of factor IX activity during dry-heat treatment was of about 3%, as estimated by a clotting assay. No substantial changes were observed in the physical and biochemical characteristics of the dry-heat-treated factor IX compared with those of the factor IX before dry-heat treatment. The dry-heat-treated factor IX was stable for up to 24 months at 4°C. The dry-heat treatment after lyophilization was an effective process for inactivating viruses. The HAV and murine encephalomyocarditis virus (EMCV) were completely inactivated to below detectable levels within 10 min of the dry-heat treatment. Porcine parvovirus (PPV) and bovine herpes virus (BHV) were potentially sensitive to the treatment. The log reduction factors achieved during lyophilization and dry-heat treatment were ≥5.60 for HAV, ≥6.08 for EMCV, 2.64 for PPV, and 3.59 for BHV. These results indicate that dry-heat treatment improves the virus safety of factor IX concentrates, without destroying the activity. Moreover, the treatment represents an effective measure for the inactivation of nonlipid enveloped viruses, in particular HAV, which is resistant to solvent/detergent treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Connell, N. M. (2003) Factor XI deficieney-from molecular genetics to clinical management.Blood Coagul. Fibrinolysis 14 Suppl 1: S59-S64.

    Article  Google Scholar 

  2. Berkman, S. A. (1988) Infectious complications of blood transfusion.Blood Rev. 2: 206–210.

    Article  CAS  Google Scholar 

  3. Mosley, J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine.Transfusion 39: 1041–1044.

    Article  CAS  Google Scholar 

  4. Klein, H. G. (2005) Pathogen inactivation technology: cleansing the blood supply.J. Intern. Med. 257: 224–237.

    Article  CAS  Google Scholar 

  5. Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.Transfusion 39: 1160–1168.

    Article  CAS  Google Scholar 

  6. Robertson, B. H. and D. D. Erdman (2000) Nonenveloped viruses transmitted by blood and blood products.Dev. Biol. Standard. 102: 29–35.

    CAS  Google Scholar 

  7. Morgenthaler, J. J. (2000) New development in plasma fractionation and virus inactivation.Vox Sang. 78 Suppl 2: 217–221.

    Google Scholar 

  8. Laub, R. and P. Strengers (2002) Parvovirus and blood products.Pathol. Biol. (Paris) 50: 339–348.

    CAS  Google Scholar 

  9. Burnouf, T. and M. Radosevich (2000) Reducing the risk of infection from plasma products: specific preventative strategies.Blood Rev. 14: 94–110.

    Article  CAS  Google Scholar 

  10. Robinson, S. M., H. Schwinn, and A. Smith (1992) Clotting factors and hepatitis A.Lancet 340: 1465.

    Article  CAS  Google Scholar 

  11. Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool.J. Med. Virol. 57: 91–99.

    Article  CAS  Google Scholar 

  12. Lawlor, E., S. Graham, E. Davidson, P. L. Yap, C. Cunningham, H. Daly, and I. J. Temperley (1996) Hepatitis A transmission by factor IX concentrates.Vox Sang. 71: 126–128.

    Article  CAS  Google Scholar 

  13. Andrewes, C. (1989)Andrewes' Viruses of Vertebrates. pp. 120–145. Balliere Tindal, London, UK.

    Google Scholar 

  14. Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004) Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma.Biotechnol. Bioprocess Eng. 9: 57–60.

    Google Scholar 

  15. Roberts, P. L. and H. Hart (2000) Comparison of the inactivation of canine and bovine parvovirus by freezedrying and dry-heat treatment in two high purity factor VIII concentrates.Biologicals 28: 185–188.

    Article  CAS  Google Scholar 

  16. Arrighi, S., R. Rossi, M. G. Borri, V. Lesnikov, M. Lesnikova, E. Franco, M. Divizia, M. E. de Santis, and E. Bucci (1995) “In vitro” and in animal model studies on a double virus-inactivation factor VIII concentrate.Thromb. Haemost. 74: 868–873.

    CAS  Google Scholar 

  17. Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst (2000) Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A.Haemophilia 6: 140–149.

    Article  CAS  Google Scholar 

  18. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability.Fed. Regist. 63: 51074–51084.

    Google Scholar 

  19. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine.Biotechnol. Bioprocess Eng. 7: 340–346.

    Article  CAS  Google Scholar 

  20. Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine.J. Microbiol. Biotechnol. 14: 140–147.

    CAS  Google Scholar 

  21. Kärber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche.Arch. Exp. Pathol. Pharmakol. 162: 480–483.

    Article  Google Scholar 

  22. Gummadi, S. N. (2003) What is the role of thermodynamics on protein stability?Biotechnol. Bioprocess Eng. 8: 9–18.

    Article  CAS  Google Scholar 

  23. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma.Biotechnol. Bioprocess Eng. 6: 25–30.

    Article  CAS  Google Scholar 

  24. Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph (1997) Rational design of stable lyophilized protein formulations: some practical advice.Pharm. Res. 14: 969–975.

    Article  CAS  Google Scholar 

  25. Murgatroyd, K. (1997) The freeze drying process. pp. 1–58. In: P. Cameron (eds.):Good Pharmaceutical Freeze-Drying Practice. Interpharm Press, Buffalo Grove, IL, USA.

    Google Scholar 

  26. Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, E. Watson, B. Flehmig, S. Lawson, and G. Frosner (1996) Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100°C.Biologicals 24: 125–130.

    Article  CAS  Google Scholar 

  27. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma.J. Microbiol. Biotechnol. 11: 497–503.

    CAS  Google Scholar 

  28. Kim, I. S. (2003) Comparative inactivation of Hepatitis A virus and Murine Encephalomyocarditis virus to various inactivation processes.Kor. J. Microbiol. 39: 242–247.

    Google Scholar 

  29. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee (2001) Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma.J. Microbiol. 39: 67–73.

    CAS  Google Scholar 

  30. Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel (2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment.Transfusion 44: 1079–1086.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Green Cross Corp., 449-900, Yongin, Korea

    Jeong Sup Shin, Yong Woon Choi & Hark Mo Sung

  2. Department of Molecular Science and Technology, College of Engineering, Ajou University, 443-749, Suwon, Korea

    Jeong Sup Shin & Yeon-Woo Ryu

  3. Department of Biological Sciences, College of Natural Sciences, Hannam University, 306-791, Daejon, Korea

    In Seop Kim

Authors
  1. Jeong Sup Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Woon Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hark Mo Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yeon-Woo Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. In Seop Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to In Seop Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shin, J.S., Choi, Y.W., Sung, H.M. et al. Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11, 19–25 (2006). https://doi.org/10.1007/BF02931863

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02931863

Keywords

Search

Navigation